WallStreetZenWallStreetZen

NASDAQ: IVA
Inventiva Sa Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for IVA

Based on 1 analyst offering 12 month price targets for Inventiva Sa.
Min Forecast
$36.00+883.61%
Avg Forecast
$36.00+883.61%
Max Forecast
$36.00+883.61%

Should I buy or sell IVA stock?

Based on 1 analyst offering ratings for Inventiva Sa.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their IVA stock forecasts and price targets.

IVA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 7%
7
BuyMaintains$36.00+883.61%2022-09-23

1 of 1

Forecast return on equity

Is IVA forecast to generate an efficient return?
Company
212.1%
Industry
22.46%
Market
122.06%
IVA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IVA forecast to generate an efficient return on assets?
Company
136.44%
Industry
13.57%
IVA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IVA earnings per share forecast

What is IVA's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$1.76
Avg 2 year Forecast
-$1.99
Avg 3 year Forecast
-$2.06

IVA revenue forecast

What is IVA's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$2.6M-75.09%
Avg 2 year Forecast
$2.2M-78.75%
Avg 3 year Forecast
$1.6M-84.01%
IVA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IVA revenue growth forecast

How is IVA forecast to perform vs Biotechnology companies and vs the US market?
Company
-44.46%
Industry
23.83%
Market
8.53%
IVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IVA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IVA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IVA$3.66$36.00+883.61%Buy
VOR$4.04$21.86+441.01%Buy
VIRX$4.08$23.00+463.73%Strong Buy
MTNB$0.72N/AN/A
BCLI$4.19$14.50+246.06%Hold

Inventiva Sa Stock Forecast FAQ

Is Inventiva Sa Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IVA) stock is to Buy IVA stock.

Out of 1 analyst, 0 (0%) are recommending IVA as a Strong Buy, 1 (100%) are recommending IVA as a Buy, 0 (0%) are recommending IVA as a Hold, 0 (0%) are recommending IVA as a Sell, and 0 (0%) are recommending IVA as a Strong Sell.

If you're new to stock investing, here's how to buy Inventiva Sa stock.

What is IVA's earnings growth forecast for 2022-2024?

(NASDAQ: IVA) Inventiva Sa's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Inventiva Sa's earnings in 2022 is -$55,965,000.On average, 2 Wall Street analysts forecast IVA's earnings for 2022 to be -$74,156,137, with the lowest IVA earnings forecast at -$75,841,504, and the highest IVA earnings forecast at -$72,892,112. On average, 2 Wall Street analysts forecast IVA's earnings for 2023 to be -$83,846,996, with the lowest IVA earnings forecast at -$85,532,363, and the highest IVA earnings forecast at -$81,740,288.

In 2024, IVA is forecast to generate -$86,796,388 in earnings, with the lowest earnings forecast at -$87,639,072 and the highest earnings forecast at -$85,953,705.

What is IVA's revenue growth forecast for 2022-2024?

(NASDAQ: IVA) Inventiva Sa's forecast annual revenue growth rate of -44.46% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Inventiva Sa's revenue in 2022 is $9,745,000.On average, 2 Wall Street analysts forecast IVA's revenue for 2022 to be $107,652,802, with the lowest IVA revenue forecast at $4,213,417, and the highest IVA revenue forecast at $211,092,187. On average, 1 Wall Street analysts forecast IVA's revenue for 2023 to be $91,852,488, with the lowest IVA revenue forecast at $91,852,488, and the highest IVA revenue forecast at $91,852,488.

In 2024, IVA is forecast to generate $69,100,037 in revenue, with the lowest revenue forecast at $69,100,037 and the highest revenue forecast at $69,100,037.

What is IVA's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: IVA) forecast ROA is 136.44%, which is higher than the forecast US Biotechnology industry average of 13.57%.

What is IVA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IVA price target, the average IVA price target is $36.00, with the highest IVA stock price forecast at $36.00 and the lowest IVA stock price forecast at $36.00.

The Wall Street analyst predicted that Inventiva Sa's share price could reach $36.00 by Sep 23, 2023. The average Inventiva Sa stock price prediction forecasts a potential upside of 883.61% from the current IVA share price of $3.66.

What is IVA's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: IVA) Inventiva Sa's current Earnings Per Share (EPS) is -$1.39. On average, analysts forecast that IVA's EPS will be -$1.76 for 2022, with the lowest EPS forecast at -$1.80, and the highest EPS forecast at -$1.73. On average, analysts forecast that IVA's EPS will be -$1.99 for 2023, with the lowest EPS forecast at -$2.03, and the highest EPS forecast at -$1.94. In 2024, IVA's EPS is forecast to hit -$2.06 (min: -$2.08, max: -$2.04).

What is IVA's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: IVA) forecast ROE is 212.1%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.